Company
Headquarters: Beijing, China
Employees: 113
CEO: Dr. Zhi Hong Ph.D.
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. It develops product candidates for the treatment of chronic hepatitis B infection, human immunodeficiency virus, MDR/XDR Gram, MDR TB mycobacteria, and Covid-19 diseases; and postpartum depression and major depressive disorder diseases. The company was incorporated in 2017 and is based in Beijing, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Brii Biosciences Ltd has the following listings and related stock indices.
Stock: HKEX: 2137 wb_incandescent